| Literature DB >> 35163038 |
Piero Portincasa1, Leonilde Bonfrate1, Mirco Vacca2, Maria De Angelis2, Ilaria Farella1, Elisa Lanza1, Mohamad Khalil1, David Q-H Wang3, Markus Sperandio4, Agostino Di Ciaula1.
Abstract
Gut microbiota encompasses a wide variety of commensal microorganisms consisting of trillions of bacteria, fungi, and viruses. This microbial population coexists in symbiosis with the host, and related metabolites have profound effects on human health. In this respect, gut microbiota plays a pivotal role in the regulation of metabolic, endocrine, and immune functions. Bacterial metabolites include the short chain fatty acids (SCFAs) acetate (C2), propionate (C3), and butyrate (C4), which are the most abundant SCFAs in the human body and the most abundant anions in the colon. SCFAs are made from fermentation of dietary fiber and resistant starch in the gut. They modulate several metabolic pathways and are involved in obesity, insulin resistance, and type 2 diabetes. Thus, diet might influence gut microbiota composition and activity, SCFAs production, and metabolic effects. In this narrative review, we discuss the relevant research focusing on the relationship between gut microbiota, SCFAs, and glucose metabolism.Entities:
Keywords: bacteria; diet; fiber; glucose homeostasis; intestine; metabolome
Mesh:
Substances:
Year: 2022 PMID: 35163038 PMCID: PMC8835596 DOI: 10.3390/ijms23031105
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Different physical and anatomical layers contributing to the intestinal barrier.
|
Microbial barrier (gut microbiota). Gut mucus, accumulating at the interface between the intestinal lumen and the brush border of enterocytes. Functional barrier, which is interplay between gastrointestinal motility and gastric acid, and biliary and pancreatic secretions. Epithelial barrier and tight junctions (enterocytes). Immunological barrier which is the combination of the immune-competent cells and their products. Gut–vascular interface. Liver barrier which represents the hepatic filter. |
Adapted from Portincasa et al. [5].
Main food groups and fiber varieties according to solubility.
| Food Group | Soluble Fibers | Insoluble Fibers |
|---|---|---|
| Cereals and grains | Nonstarch polysaccharides | Nonstarch polysaccharides |
| Hemicellulose | Hemicellulose | |
| Resistant oligosaccharides | Resistant starch | |
| Inulin | ||
| Fruits and vegetables | Nonstarch polysaccharides | Nonstarch polysaccharides |
| Hemicellulose | Hemicellulose | |
| Resistant oligosaccharides | Lignin | |
| Inulin | Resistant starch | |
| Legumes and pulses | Nonstarch polysaccharides | Nonstarch polysaccharides |
| Hemicellulose | Hemicellulose | |
| Lignin | ||
| Resistant starch |
Adapted from Swann et al., 2019 [18], and the Institute of Medicine, 2005 [17].
Figure 1Pathways involved in the biosynthesis of SCFAs from dietary fiber and carbohydrate fermentation by the colonic microbiota. The three major SCFAs are: (1) acetate which originates via the Wood–Ljungdahl pathway or acetyl-CoA; (2) butyrate synthesized from two molecules of acetyl-CoA; (3) propionate from PEP involving the acrylate pathway or the succinate pathway or the propanediol pathway after microbial transformation of fucose and rhamnose. Abbreviations: PEP—phosphoenolpyruvate; DHAP—dihydroxyacetone phosphate. Adapted from Kho et al. [31].
Figure 2Chemical formula, molecular weight, and 3D structure of the three main short chain fatty acids acetate (C2), propionate (C3), and butyrate (C4). In the 3D structure, atoms appear as hydrogen in white color, carbon as grey color, and oxygen as red color. https://pubchem.ncbi.nlm.nih.gov/ (accessed 18 January 2022).
Dietary source, fiber substrates, and SCFA-producing bacteria.
| Dietary Source | Substrates | Fermenting Genera |
|---|---|---|
| Cashew, green banana, white beans, oat, and potato | Resistant starch | |
| Seaweed and cereal bran | Cellulose | |
| Cereal bran | Hemi-celluloses (xylan and arabinoxylan) | |
| Apples, apricots, cherries, oranges, and carrots | Pectin | |
| Asparagus, leek, onions, banana, wheat, garlic, chicory, and artichoke | Fructans (inulin and fructooligosaccharides) | |
| Breast milk | Milk oligosaccharides |
|
| Milk, yogurt, buttermilk, and cheese | Lactose (only in lactose-intolerant people) |
|
| Oat, barley, wheat, rye, mushrooms, and seaweed | β-Glucan | |
| Acacia tree and prepared food additive | Gum arabic | |
| Guar bean and prepared food additive | Guar gum | |
| Seaweed | Laminarin |
|
| Artichoke, beans, beetroot, broccoli, chickpeas, fennel, lentils, lettuce, radicchio, and onion | Galacto-oligosaccharides |
|
| Cottonseed flour, soy flour, onions, chickpeas, beans, peas, and lentils | Raffinose and stachyose |
Adapted from [35,36,37].
Figure 3Interplay between the microbiota-accessible carbohydrates (MACs), the gut microbiota, the production short chain fatty acids (SCFAs), and the enterocytes (mainly colonocytes). The main pathways involved are summarized in the two enterocytes. (1) Following initial digestion and intestinal transit, the dietary MACs meet the gut microbiota, which is characterized by high and physiological diversity and no bacterial overgrowth. (2) SCFA-producing bacteria, mainly in the colon, will digest MACs and increase the luminal content of SCFAs. (3) In this environment, the abundance of A. muciniphila increases and is associated with protective effects on mucin and tight junction integrity. (4) In addition, a diet enriched in MACs will positively stimulate the immune system, leading to plasma cell-mediated production of immunoglobulins A (IgA) with further control on microbiota function, diversity, and prevention of overgrowth. (5) In the colonocyte, SCFAs are absorbed by colonocytes via passive diffusion or via active transport mediated by H+-dependent monocarboxylate transporters (MCTs). (6) The SCFAs acetate, butyrate, and propionate are converted to acetyl-CoA or propynyl-CoA by pathways involving the acetyl-CoA carboxylases (ACSSs) and beta oxidation. (7) This step produces ATP, which contributes to the maintenance of cell homeostasis, including the function of tight junctions. (8) Via stimulation of receptors at the apical membrane, SCFAs promote the secretion of gut hormones, such as glucagon-like peptide 1 (GLP1) and peptide YY (PYY), γ-aminobutyric acid (GABA), and serotonin (5-HT). At this level, butyrate inhibits (-) histone deacetylases (HDACs) with consequent anti-inflammatory effect by reducing NF-κB-induced pro-inflammatory mediators, such as TNF-α, IL-6, IL-12, and iNOS [43]. (9) Intracellular SCFAs contribute to inhibition (-) of HDAC. Acetate activates the inflammasome nucleotide-binding oligomerization domain 3 (NLRP3) with secretion of the protective IL-18 from epithelial cells, which maintains the tight junction’s function. (10) Colon-derived SCFAs reach the systemic circulation promoting anti-inflammatory and immunomodulatory effects as well as increasing insulin secretion, maintaining energy homeostasis, and improving liver and brain function.
Effects of SCFAs on intestinal epithelial cell homeostasis and function.
|
Energy substrate for ATP production. Receptor activation, mainly G protein-coupled receptors. Maintenance of barrier function and integrity. In particular, modulation of apical tight junctions, activation of NLRP3 inflammasome, increased mucin expression, anti-inflammatory effects, interaction with epithelial Toll-like receptors, and activation of the nuclear factor-κB signaling pathway. Modulation of immunity and control of inflammation. Treg differentiation, modulation of inflammation mediators. Modulation of intracellular permeability. Epigenetic effects, with inhibition of histone deacetylases, hyperacetylation of histones, and modulation of gene expression. |
Observational studies pointing to the role of SCFAs in the maintenance of glucose homeostasis, in pre-diabetes and T2DM.
| Author, Year | Study Groups | Number (M/F) | BMI (Kg/m2) | Major Findings |
|---|---|---|---|---|
| Wu et al., 2020 [ | Healthy individuals | 206 | 28.2 | In pre-diabetes and patients with T2DM ↓ abundance of butyrate-producing bacteria. |
| Pre-diabetes | 220 | 28.3 | ||
| T2DM | 58 | 31.6 | ||
| Sanna et al., 2019 [ | Healthy individuals selected on the basis of SCFAs and genome, fecal metagenomic sequences. | 952 | - | Butyrate-producing bacteria have a protective role against T2DM. |
| Garcia-Mantrana et al., 2018 [ | Healthy individuals | 27 | 19–28 | Evaluation by food frequency questionnaire. |
| Mitsou et al., 2017 [ | Healthy individuals | 116 | 25–30 | Evaluation by food frequency questionnaire. |
| Gutierrez-Diaz et al., 2016 [ | Healthy individuals with low adherence to Mediterranean diet. | 10 | 21.2–31.2 | Evaluation by food frequency questionnaire. |
| Healthy individuals with high adherence to Mediterranean diet. | 21 | 21.6–31.0 | ||
| De Filippis et al., 2016 [ | Vegetarian individuals | 51 | 19.4–24.4 | Vegetarian diet, vegan diet, and omnivore; high adherence to Mediterranean diet associated with ↑ abundance of |
| Vegan individuals | 51 | 19.1–23.5 | ||
| Omnivore individuals | 51 | 20.1–24.1 | ||
| Zhang et al., 2013 [ | Healthy individuals | 44 | 23.4 | In healthy individuals ↑ abundance of butyrate-producing bacteria ( |
| Pre-diabetes | 64 | 24.9 | ||
| T2DM | 13 | 26.5 | ||
| Karlsson et al., 2013 [ | Healthy individuals | 43 | 20–40 | In healthy individuals ↑ abundance of |
| Pre-diabetes | 49 | |||
| T2DM | 53 | |||
| Quin et al., 2012 [ | Healthy individuals | 182 | 18–40 | In healthy individuals ↑ abundance of |
| T2DM | 183 | |||
| De Filippo et al., 2010 [ | African children (1–6 yrs) | 14 | Evaluation by food frequency questionnaire. | |
| Italian children (1–6 yrs) | 15 |
Abbreviations: ↓—significant decrease; ↑—significant increase; BMI—body mass index; SCFAs— short chain fatty acids; T2DM— type 2 diabetes.
Randomized clinical trials pointing to the role of SCFAs in the maintenance of glucose homeostasis, in metabolic syndrome, and in type 2 diabetes.
| Author | Study Groups | Number | BMI | Study Design | Duration | Intervention | Major Findings |
|---|---|---|---|---|---|---|---|
| Vitale et al., 2021 [ | At least one criterion of MetS | 29 | 25–35 | Parallel | 8 weeks | Mediterranean diet consisting of fiber 19.3 g/1000 kcal compared with | ↑ |
| Zhao et al., 2018 [ | Type 2 DM | 43 | 25–35 | Parallel | 12 weeks | High-fiber diet consisting of fiber 37.1 g compared with control diet consisting of fiber 16.1 g | ↑ Fecal butyrate |
| Haro et al., 2016 [ | MetS | 20 | 30–40 | Parallel | 1 year | Mediterranean diet consisting of fiber: 12.9 ± 0.2 g/Kcal mainly from vegetables compared with high-fiber diet consisting of fiber: 14.1 ± 0.2 g/1000 kcal, mainly form wholegrains | ↑ |
| Hald et al., 2016 [ | MetS | 19 | 25.9–41 | Crossover | 4 weeks | Diet enriched with Arabinoxylan and Resistant starch consisting of fiber 64 g compared with Western diet consisting of fiber 17.6 g | ↑ |
| Vetrani et al., 2016 [ | MetS | 40 | 25–35 | Parallel | 12 weeks | Wholegrain diet consisting of total fiber 40 g with fiber from cereal 28.9 g, compared with refined cereal diet consisting of total fiber 22.1 g with fiber from cereal 11.8 g | ↑ Plasma propionate |
| Kovatcheva-Datchary et al., 2015 [ | Healthy individuals | 39 | 18–28 | Parallel | 3 days | Barley kernel-based bread consisting of fiber 37.6 g compared with white wheat bread consisting of fiber 9.1 g | ↑ |
| Nilsson et al., 2015 [ | Healthy individuals | 20 | 18–28 | Crossover | 3 days | Barley kernel-based bread consisting of fiber 37.6 g compared with white wheat bread consisting of fiber 9.1 g | ↑ Plasma SCFAs |
| David et al., 2014 [ | Healthy individuals | 10 | 19–32 | Crossover | 4 days | Plant-based diet consisting of fiber 26 g/1000 kcal compared with Western diet consisting of fiber 9.3 g/1000 kcal | ↑ |
| Freeland et al., 2010 [ | Hyperinsulinaemic individuals | 28 | 24–27 | Parallel | 1 year | High-wheat fiber cereal consisting of 24 g fiber/day compared with low-fiber cereal | ↑ Acetate and butyrate concentrations |
Abbreviations: ↓—significant decrease; ↑—significant increase; BMI—body mass index; HbA1c—glycated hemoglobin; GLP-1—glucagon-like peptide-1; MetS—metabolic syndrome; SCFAs—short chain fatty acids.
Figure 4Glucose metabolism is influenced by short chain fatty acids (SCFAs), systemically, at various levels [120]. Main target organs include adipocytes, liver, pancreas, skeletal muscle, intestine, and brain where pathways govern mechanisms, which include receptors, synthesis, hormones, and perception. Abbreviations: GLP-1—glucagon-like peptide-1; GLUT-4—activated glucose transporter protein-4; GPR—G-protein-coupled receptors; PYY—peptide YY; A—acetate; P—propionate; B—butyrate.